Danaher (DHR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
14 May, 2026Opening remarks and agenda
Meeting called to order with agenda and procedures available online.
Introduction of board members and independent auditor from Ernst & Young.
Record date for voting set as March 6, 2026, with proper notice and proxy statement distribution confirmed.
Inspector of Election appointed, quorum confirmed, and polls opened for voting.
Four items of business outlined, with no additional shareholder proposals introduced.
Board and executive committee updates
Board nominees for director positions presented for election to serve until the 2027 annual meeting.
Board recommends approval of all four proposals, including director elections and incentive plan.
Overview of voting outcomes
All director nominees elected by majority vote.
Ernst & Young reappointed as independent auditor with 94.32% approval.
Advisory vote on executive compensation passed with 93.01% approval.
Amended and restated omnibus incentive plan approved with 93.03% approval.
Latest events from Danaher
- Strong growth in bioprocessing and diagnostics supports a positive full-year outlook.DHR
Bank of America Global Healthcare Conference 202613 May 2026 - Bioprocessing and diagnostics drive growth outlook, with Masimo acquisition boosting long-term returns.DHR
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Q1 2026 revenue up 3.5% to $6.0B, adjusted EPS up 9.5%, Masimo acquisition announced.DHR
Q1 202621 Apr 2026 - Strong 2025 results, robust recurring revenue, and innovation drive long-term growth outlook.DHR
Corporate presentation21 Apr 2026 - Director elections, auditor ratification, and executive pay up for vote at May 2026 meeting.DHR
Proxy filing25 Mar 2026 - 2026 proxy covers director elections, pay, auditor, incentive plan, and major acquisition.DHR
Proxy filing25 Mar 2026 - 2025 ended with strong growth and cash flow; 2026 guidance targets higher revenue and EPS.DHR
Q4 20253 Feb 2026 - Q2 2024 revenue fell 3%, margin improved, and $4.6B was spent on share repurchases.DHR
Q2 20243 Feb 2026 - High single-digit growth and margin expansion driven by innovation and global diagnostics leadership.DHR
Investor Day 202422 Jan 2026